Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 5
2007 5
2009 3
2010 6
2011 3
2012 7
2013 4
2014 3
2015 4
2016 6
2017 2
2018 3
2019 3
2020 3
2021 5
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Peyrin-Biroulet L, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798039 Free article. Clinical Trial.
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J; HIBISCUS Study Group. Rubin DT, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):17-27. doi: 10.1016/S2468-1253(21)00338-1. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798036 Clinical Trial.
Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T-Cell Activation in the Heart and Promote Cardiac Dysfunction.
Ngwenyama N, Kirabo A, Aronovitz M, Velázquez F, Carrillo-Salinas F, Salvador AM, Nevers T, Amarnath V, Tai A, Blanton RM, Harrison DG, Alcaide P. Ngwenyama N, et al. Among authors: velazquez f. Circulation. 2021 Mar 23;143(12):1242-1255. doi: 10.1161/CIRCULATIONAHA.120.051889. Epub 2021 Jan 19. Circulation. 2021. PMID: 33463362 Free PMC article.
Increased lymphocyte activation and atherosclerosis in CD47-deficient mice.
Engelbertsen D, Autio A, Verwilligen RAF, Depuydt MAC, Newton G, Rattik S, Levinsohn E, Saggu G, Jarolim P, Wang H, Velazquez F, Lichtman AH, Luscinskas FW. Engelbertsen D, et al. Among authors: velazquez f. Sci Rep. 2019 Jul 23;9(1):10608. doi: 10.1038/s41598-019-46942-x. Sci Rep. 2019. PMID: 31337788 Free PMC article.
61 results